Clik here to view.
FDA approves HIFU for “prostate tissue ablation”
According to a media release issued by SonaCare Medical early this morning, the company has received approval from the U.S. Food and Drug Administration (FDA) to market its Sonablate® 450 technology in...
View ArticleClik here to view.
Is there ANY role for estramustine phosphate in treatment of CRPC today?
The appropriate, individual treatment of men with metastatic and non-metastatic forms of castration-resistant prostate cancer (CRPC) has become vastly more complicated over the past 5 years. After the...
View ArticleClik here to view.
The direct “financial toxicity” of cancer diagnosis and treatment
An interesting new paper in Cancer has offered us a sophisticated assessment of the effects of a diagnosis of and treatment for cancer on employment and income of all adults (aged 18 and older) and of...
View ArticleClik here to view.
What it really costs to manage/treat low-risk prostate cancer
In a new article in the journal Cancer, a research group associated primarily with the University of California, Los Angeles, have provided detailed information on the costs of first-line management of...
View ArticleClik here to view.
The “best” form of first-line treatment for clinically significant, localized...
From the perspective of the disinterested observer, one of the very least edifying aspects of issues related to the management of prostate cancer has been the nearly 50-year-long “discussion” between...
View ArticleClik here to view.
Contemporary treatment decision-making at an equal access, multidisciplinary,...
A new paper in Urologic Oncology describes what appears to be one of the first prospective cohort studies to examine treatment decision-making by newly diagnosed prostate cancer patients within a...
View ArticleClik here to view.
Unexpected and perhaps intriguing data from the STAMPEDE trial
In a poster presentation to be given at the upcoming Genitourinary Cancers Symposium in San Francisco later this week, data from the STAMPEDE trial in the UK appear to have demonstrated a result that...
View ArticleClik here to view.
Prostate cancer, cardiovascular disease, and the role of ADT
A new trial to be discussed at the Genitourinary Cancers Symposium is the RADICAL-PC trial, designed to give us a greater understanding of the roles of androgen deprivation (ADT) and other factors in...
View ArticleClik here to view.
Of liquid biopsies, CTCs, and first-line treatment for mCRPC
A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy...
View ArticleClik here to view.
NCCN issues revised prostate cancer management guidelines for 2016
The National Comprehensive Cancer Consortium (NCCN) has just released its updated 2016 guidelines on the management of prostate cancer for physicians. The list of changes to the guidelines from the...
View ArticleClik here to view.
ICER/Families USA “Proven Best Choices” for treatment of low-risk prostate...
According to a report from Kaiser Health News, the consumer organization Families USA is collaborating with the Institute for Clinical and Economic Review (ICER) to provide a series of “Proven Best...
View ArticleClik here to view.
ED drugs and risk for prostate cancer recurrence? … NOT!
Back in February 2015 a group of German researchers published a study suggesting that there was a small but significantly increased risk of biochemical recurrence after prostate cancer treatment among...
View ArticleClik here to view.
Data from a prospective trial of HIFU-based hemiablation for localized...
A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was...
View ArticleClik here to view.
Estimation of life expectancy for newly diagnosed men with prostate cancer
A critical question for every patient newly diagnosed with prostate cancer is going to be, “How long am I going to live”? That question may be particularly important if a second and associated question...
View ArticleClik here to view.
Early data on efficacy, safety of PSMA-linked lutetium-177
There has been a good deal of optimism about the potential efficacy and safety of the radioisotope-labeled product known as prostate-specific membrane antigen-linked lutetium-177 (177Lu-PSMA) in the...
View ArticleClik here to view.
Efficacy and safety in the curative treatment of progressive, lymph...
The salvage treatment of men found to have positive lymph nodes after prior (surgical) treatment and the identification of such positive lymph nodes using techniques such as [11C]choline PET/CT scans...
View ArticleClik here to view.
Are you a good candidate for the TAPUR study? If so, sign up!
Nearly a year ago now, the American Society of Clinical Oncology (ASCO) first announced plans to initiate an innovative trial of a personalized medicine initiative called the Targeted Agent and...
View ArticleClik here to view.
Individualizing precision therapy for advanced prostate cancer
There’s a very interesting article this week on the Hutch News pages of the Fred Hutchinson Cancer Research Center (in Seattle, WA). It addresses the degree to which metastatic prostate cancer may be...
View ArticleClik here to view.
Time from diagnosis to initiation of primary radiation therapy: does it...
Patients are often concerned about delaying initiation of treatment. Will it give the cancer a chance to metastasize? What if the random biopsy didn’t detect existing higher grade cancer? This is...
View ArticleClik here to view.
Longer life or quality of life? What do newly diagnosed patients really want?
A third, and interesting, late-breaking poster to be presented at the upcoming annual meeting of the American Urological Association looked into patient perspectives on quality of life as opposed to...
View Article